Cellectis Hosts World’s First Gene Edited Dinner in NYC

NEW YORK–(BUSINESS WIRE)– class= »bwalignl »>
Regulatory News:

Cellectis
(Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a
biopharmaceutical company focused on developing immunotherapies based on
gene edited CAR T-cells (UCART), today announced that the Company, along
with its agricultural biotech subsidiary, Calyxt,
hosted the world’s first dinner made with gene edited foods.

The dinner held on Thursday, Oct. 20, 2016 in New York required a
six-month preparation time entrusted to The Lab-Ducasse Conseil’s chefs
and experts with a series of trials where the ingredients were cooked
and tasted in a variety of ways.

Attendees included university professors, doctors, reporters,
celebrities, entrepreneurs and key opinion leaders.

The six-course dinner was comprised of a variety of foods that
incorporated a selection of Calyxt’s recently harvested gene edited
high-oleic soybeans and potatoes. The dinner featured Tofu and soy
burgers, Hummus soy, gilt-headbream, lemon, Oven-baked potato pie or Soy
with marinated fish and caviar, among other dishes. Calyxt uses its
innovative TALEN® technology to create foods with healthier
characteristics by making precise deletions in a crop’s DNA, without
adding any foreign DNA.

“This dinner – truly a meal of the 21^st century – marks a
groundbreaking milestone for both Cellectis and Calyxt,” said Dr. André
Choulika, Cellectis CEO and Calyxt president. “It not only represents a
historic moment for the food, agriculture and biotech industries but
also for people all over the world who are in search of an answer to
address some of the biggest health issues in today’s society. This meal
is a clear indicator of how gene editing will ultimately transform what
we put on our plates in the near future. This was the first harvest
dinner, and millions of people will be able to experience these same
foods in the near future.”

“Gene editing holds an immense potential to improve lives and nutrition
while minimizing our environmental footprint through the foods that we
produce and eat,” added Federico Tripodi, Calyxt CEO. “We believe that
Calyxt’s high-quality food ingredients will meet the challenges that are
related to sustainable growth and climate change, while simultaneously
addressing societal issues like obesity, diabetes and high cholesterol /
blood pressure. The possibilities are endless; every day, consumers are
increasingly mindful of the foods that they eat, and our products will
be developed to help families meet those needs. This dinner was the
first step to achieving this reality and positively impacting consumers’
lives in the months and years to come.”

Photos from the meal and the full menu are available upon request.

About Cellectis

Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company’s
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 16 years of expertise
in genome engineering – based on its flagship TALEN® products and
meganucleases and pioneering electroporation PulseAgile technology – to
create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis’ goal is to create innovative products in multiple fields and
with various target markets. Cellectis is listed on the Nasdaq market
(ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find
out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark
owned by the Cellectis Group.

About Calyxt

Calyxt,
Inc. is a fast-growing, consumer-oriented ag company that utilizes
its innovative, patented TALEN® technology to usher in a new era of
agriculture and develop crop products with healthier characteristics for
consumers – all the while helping farmers and food and agriculture
industries reduce their environmental footprints in the context of
climate change. Calyxt believes that agricultural technologies can have
a profound, positive impact on humanity and is looking to engage those
who share this passion for food and agriculture. Calyxt is located in
Minneapolis-St. Paul, Minn., and is a wholly owned subsidiary of Cellectis.

For further information please visit our website: www.calyxt.com

Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.

Disclaimer

This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company’s
objectives based on the current expectations and assumptions of the
Company’s management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161031006162/en/